TABLE 5
FROM:
A phase 1 study of tazarotene in adults with advanced cancer
P H Jones, R D Burnett, I Fainaru, P Nadolny, P Walker, Z Yu, D Tang-Liu, T S Ganesan, D C Talbot, A L Harris and G J S Rustin
BACK TO ARTICLETable 5. Summary of the pharmacokinetic parameters of tazarotenic acid following single-dose oral administration of Tazarotene on day 0 and at 12 weeks
| Dose taken (mg) | Cmax day 0 (ng ml-1) | Tmax day 0 (h) | AUC0–inf day 0 (ng h ml-1) | T1/2 day 0 (h) | Cmax week 12 (ng ml-1) |
|---|---|---|---|---|---|
| 1.4 | 40.8 18.3 | 3.23.5 | 19538 | 5.62 0.86 | 29.6 |
| (N=6) | (20.4, 41.7, 66.3) | (1, 1, 9) | (159, 188, 243) | (4.62, 5.65, 6.78) | (N=6) |
| 2.1 | 68.827.8 | 3.63.3 | 27964 | 8.363.59 | 41.9 |
| (N=5) | (35.2, 73.2, 107) | (1, 3, 9) | (204, 308, 353) | (5.35, 8.14, 14.3) | (N=3) |
| 2.8 | 70.828.1 | 2.71.5 | 39460 | 7.962.87 | 89.4 |
| (N=3) | (45.4, 65.9, 101) | (1, 3, 4) | (328, 412, 443) | (4.81, 8.67, 10.4) | (N=1) |
| 4.2 | 72.92.1 | 3.53.5 | 3591 | 4.050.36 | 97.8 |
| (N=2) | (71.4, 72.9, 74.3) | (1, 3.5, 6) | (358, 359, 360) | (3.79, 4.05, 4.30) | (N=1) |
| 8.4 | 12696 | 2.50.7 | 6143 | 14.29.6 | — |
| (N=2) | (57.8, 126, 194) | (2, 2.5, 3) | (612, 614, 616) | (7.44, 14.2, 21.0) | |
| 16.8 | 377112 | 3.01.0 | 1751358 | 15.414.3 | 325 |
| (N=3) | (306, 318, 506) | (2, 3, 4) | (1341, 1915, 1998) | (1.25, 15.0, 29.9) | (N=3) |
| 25.2 | 561236 | 2.11.1 | 2394841 | 3.332.56 | 367 |
| (N=7) | (191, 559, 859) | (1, 2, 4) | (1540, 2287, 3677) | (1.32, 2.35, 8.53) | (N=1) |
| 33.6 | 903267 | 1.50.6 | 3467707 | 8.016.51 | 829 |
| (N=4) | (680, 823, 1286) | (1, 1.5, 2) | (2809, 3425, 4208) | (1.20, 7.90, 15.1) | (N=1) |
Pharmacokinetic parameters are presented as means.d. (minimum, median and maximum).
